ଆବାଲୋପାରାଟାଇଡ

ଆବାଲୋପାରାଟାଇଡ
Clinical data
Trade namesTymlos, Eladynos
SynonymsBA058, BIM-44058
AHFS/Drugs.commonograph
MedlinePlusa617038
Routes of
administration
Subcutaneous injection
Legal status
Legal status
Identifiers
  • L-alanyl-L-valyl-L-seryl-L-α-glutamyl-L-histidyl-L-glutaminyl-L-leucyl-L-leucyl-L-histidyl-L-α-aspartyl-L-lysylglycyl-L-lysyl-L-seryl-L-isoleucyl-L-glutaminyl-L-α-aspartyl-L-leucyl-L-arginyl-L-arginyl-L-arginyl-L-α-glutamyl-L-leucyl-L-leucyl-L-α-glutamyl-L-lysyl-L-leucyl-L-leucyl-2-methylalanyl-L-lysyl-L-leucyl-L-histidyl-L-threonyl-L-alaninamide
Chemical and physical data
FormulaC174H299N56O49
Molar mass୩,୯୫୯.୬୫ g·mol−1
3D model (JSmol)
  • CC[C@H](C)[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)NC(C)(C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C)C(=O)N)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)CNC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](Cc2cnc[nH]2)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](Cc3cnc[nH]3)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C)N
  • InChI=1S/C174H300N56O49/c1-26-93(20)136(228-165(274)126(80-232)224-141(250)101(39-28-32-56-176)200-129(236)78-195-140(249)100(38-27-31-55-175)201-161(270)123(73-133(243)244)223-160(269)121(71-98-76-190-82-197-98)220-158(267)118(68-90(14)15)216-155(264)114(64-86(6)7)213-148(257)107(45-50-127(180)234)207-159(268)120(70-97-75-189-81-196-97)219-151(260)111(49-54-132(241)242)209-164(273)125(79-231)225-167(276)135(92(18)19)227-139(248)94(21)179)168(277)210-108(46-51-128(181)235)149(258)222-124(74-134(245)246)162(271)217-112(62-84(2)3)152(261)205-105(44-37-61-194-173(187)188)143(252)203-103(42-35-59-192-171(183)184)142(251)204-104(43-36-60-193-172(185)186)144(253)206-110(48-53-131(239)240)150(259)214-115(65-87(8)9)154(263)215-113(63-85(4)5)153(262)208-109(47-52-130(237)238)147(256)202-102(40-29-33-57-177)145(254)211-116(66-88(10)11)156(265)218-119(69-91(16)17)166(275)230-174(24,25)170(279)226-106(41-30-34-58-178)146(255)212-117(67-89(12)13)157(266)221-122(72-99-77-191-83-198-99)163(272)229-137(96(23)233)169(278)199-95(22)138(182)247/h75-77,81-96,100-126,135-137,231-233H,26-74,78-80,175-179H2,1-25H3,(H2,180,234)(H2,181,235)(H2,182,247)(H,189,196)(H,190,197)(H,191,198)(H,195,249)(H,199,278)(H,200,236)(H,201,270)(H,202,256)(H,203,252)(H,204,251)(H,205,261)(H,206,253)(H,207,268)(H,208,262)(H,209,273)(H,210,277)(H,211,254)(H,212,255)(H,213,257)(H,214,259)(H,215,263)(H,216,264)(H,217,271)(H,218,265)(H,219,260)(H,220,267)(H,221,266)(H,222,258)(H,223,269)(H,224,250)(H,225,276)(H,226,279)(H,227,248)(H,228,274)(H,229,272)(H,230,275)(H,237,238)(H,239,240)(H,241,242)(H,243,244)(H,245,246)(H4,183,184,192)(H4,185,186,193)(H4,187,188,194)/t93-,94-,95-,96+,100-,101-,102-,103-,104-,105-,106-,107-,108-,109-,110-,111-,112-,113-,114-,115-,116-,117-,118-,119-,120-,121-,122-,123-,124-,125-,126-,135-,136-,137-/m0/s1
  • Key:BVISQZFBLRSESR-XSCWXTNMSA-N

ଆବାଲୋପାରାଟାଇଡ, ଅନ୍ୟମାନଙ୍କ ମଧ୍ୟରେ ଏକ ବେପାର ନାମ ଟାଇମଲୋସ୍, ଏକ ଔଷଧ ଯାହା ଋଉତୁବନ୍ଦ ପରବର୍ତ୍ତୀ ଓଷ୍ଟିଓପୋରୋସିସ ରୋଗର ଚିକିତ୍ସା ପାଇଁ ବ୍ୟବ‌ହୃତ ହୁଏ ।[] ଅଧିକ ସଙ୍କଟରେ ଥିବା ରୋଗୀର ହାଡ଼ ଭଙ୍ଗା ଆଶଙ୍କା ଏହି ଔଷଧ ୫.୯%ରୁ ୩.୩%କୁ ହ୍ରାସ କରିପାରେ । [] ଏହାକୁ ଦୁଇ ବର୍ଷରୁ ଅଧିକ ସମୟ ଧରି ବ୍ୟବହାର କରିବା ଉଚିତ୍ ନୁହେଁ । [] ଏହା ଚର୍ମ ତଳେ ଏକ ଇଞ୍ଜେକ୍ସନ୍ ଭାବରେ ବ୍ୟବହୃତ ହୁଏ । []

ସାଧାରଣ ପାର୍ଶ୍ୱ ପ୍ରତିକ୍ରିୟାରେ ଦୃତ ହୃତ୍‌ପିଣ୍ଡ ଗତି, ମୁଣ୍ଡ ହାଲୁକା ଲାଗିବା, ବାନ୍ତି, ମୁଣ୍ଡବିନ୍ଧା, ଥକାପଣ ଏବଂ ଉପର ପେଟ ଯନ୍ତ୍ରଣା ହୋଇପାରେ । [] [] ଅନ୍ୟାନ୍ୟ ସମ୍ଭାବ୍ୟ ସଙ୍କଟ ମଧ୍ୟରେ ଅଷ୍ଟିଓସାର୍କୋମା, ଉଚ୍ଚ ରକ୍ତ କ୍ୟାଲସିୟମ୍, ଠିଆ ହେବା ସହିତ ନିମ୍ନ ରକ୍ତଚାପ ଏବଂ ଇଞ୍ଜେକ୍ସନ୍ ସ୍ଥାନରେ ଯନ୍ତ୍ରଣା ହେବାର ଆଶଙ୍କା ରହିଛି । [] [] ଏହା ଏକଏଡ ହରମୋନ ସମ୍ବନ୍ଧୀୟ ପୁଷ୍ଟିସାର ଆନାଲଗ (PTHrP) ଯାହା ହାଡ଼ର ବୃଦ୍ଧିକୁ ପ୍ରୋତ୍ସାହିତ କରି କାର୍ଯ୍ୟକ୍ଷମ ହୁଏ ।[]

୨୦୧୭ ମସିହାରେ ଯୁକ୍ତରାଷ୍ଟ୍ରରେ ଚିକିତ୍ସା ବ୍ୟବହାର ପାଇଁ ଆବାଲୋପାରାଟାଇଡ୍ ଅନୁମୋଦିତ ହୋଇଥିଲା। [] ୟୁରୋପରେ ଏହାର ମାନ ନିରୁପଣ ସଠିକ ନ ଥିବା ଯୋଗୁ ଅନୁମୋଦନ କରାଯାଇନଥିଲା ।[] ୨୦୧୮ ସୁଦ୍ଧା ଯୁକ୍ତରାଷ୍ଟ୍ରରେ ଏହାର ମାସିକ ଖର୍ଚ୍ଚ ପ୍ରାୟ ୧୮୦୦ ଡଲାର୍ ଥିଲା । [] ୨୦୧୯ ସୁଦ୍ଧା ଏହାର ପ୍ରଭାବ କମ୍ ଦାମୀ ବାଇଫସଫୋନେଟ ସହିତ କିପରି ତୁଳନା କରାଯାଏ ତାହା ଅସ୍ପଷ୍ଟ । []

  1. ୧.୦ ୧.୧ ୧.୨ "Abaloparatide Monograph for Professionals". Drugs.com (in ଇଂରାଜୀ). Archived from the original on 5 March 2021. Retrieved 17 July 2021.
  2. ୨.୦ ୨.୧ ୨.୨ Benjamin F. Simmons, I. I. I.; Caprio, Anthony J. (15 February 2019). "Abaloparatide (Tymlos) for Osteoporosis". American Family Physician. 99 (4): 260–261. ISSN 0002-838X. Archived from the original on 20 January 2021. Retrieved 17 July 2021.
  3. ୩.୦ ୩.୧ ୩.୨ ୩.୩ "Abaloparatide Monograph for Professionals". Drugs.com (in ଇଂରାଜୀ). Archived from the original on 5 March 2021. Retrieved 17 July 2021.
  4. ୪.୦ ୪.୧ Benjamin F. Simmons, I. I. I.; Caprio, Anthony J. (15 February 2019). "Abaloparatide (Tymlos) for Osteoporosis". American Family Physician. 99 (4): 260–261. ISSN 0002-838X. Archived from the original on 20 January 2021. Retrieved 17 July 2021.
  5. "Eladynos". Archived from the original on 3 March 2021. Retrieved 17 July 2021.